翰宇药业：司美格鲁肽两大适应症临床试验收官在即

Core Viewpoint - Hanyu Pharmaceutical is making significant progress in the clinical trials of Semaglutide for weight loss and diabetes treatment, with both trials entering the final stages and expected to complete follow-up work by early 2026 [1] Group 1: Clinical Trial Progress - The clinical trial for Semaglutide's weight loss indication has completed treatment visits for all participants, with follow-up work nearing completion [1] - The clinical trial for Semaglutide's diabetes indication is also progressing smoothly, with all follow-up work expected to conclude by January 2026 [1] - The complete clinical research reports for both indications are anticipated to be finalized by the end of March 2026 [1] Group 2: Commercialization Strategy - Hanyu Pharmaceutical has proactively established key commercial partnerships, notably with 3SBio, to enhance the commercialization of Semaglutide [1] - The company leverages its strong R&D capabilities to ensure efficient clinical research execution, while 3SBio provides established commercial operations and distribution channels [1] - The completion of clinical reports, advancement of market application submissions, and comprehensive support from commercial partners are expected to enrich the product portfolio and drive robust growth for the company [1]